Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Extensively Drug-Resistant Tuberculosis"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 533
Tytuł:
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Autorzy:
Patil SB; Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Pune, India.
Tamirat M; Partners In Health, Maseru, Lesotho.
Khazhidinov K; Partners In Health, Astana, Kazakhstan.
Ardizzoni E; Institute of Tropical Medicine (ITM), Antwerp, Belgium.
Atger M; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Austin A; UCSF Center for Tuberculosis, University of California, , San Francisco, San Francisco, CA, USA.
Baudin E; Epicentre, Paris, France.
Bekhit M; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Bektasov S; National TB Center, Almaty, Kazakhstan.
Berikova E; Partners In Health, Astana, Kazakhstan.; National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan.
Bonnet M; Université de Montpellier, IRD, INSERM, Montpellier, TransVIHMI, France.
Caboclo R; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Chaudhry M; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Chavan V; Médecins Sans Frontières, Mumbai, India.
Cloez S; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Coit J; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Coutisson S; Médecins Sans Frontières, Geneva, Switzerland.
Dakenova Z; City Center of Phthisiopulmonology, Astana, Kazakhstan.
De Jong BC; Institute of Tropical Medicine (ITM), Antwerp, Belgium.
Delifer C; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Demaisons S; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Do JM; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Dos Santos Tozzi D; Incyte, Morges, Switzerland.
Ducher V; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Ferlazzo G; Médecins Sans Frontières, Geneva, Switzerland.
Gouillou M; Epicentre, Paris, France.
Khan U; Interactive Research and Development (IRD) Global, Singapore, Singapore.
Kunda M; Partners In Health, Maseru, Lesotho.
Lachenal N; Médecins Sans Frontières, Geneva, Switzerland.
LaHood AN; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Lecca L; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.; Socios En Salud-Sucursal Peru, Lima, Peru.
Mazmanian M; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.; Assistance Publique Hôpitaux de Paris (APHP), Unité de Recherche Clinique, Hôpital Pitié-Salpêtrière, Paris, France.; Santé Arménie French-Armenian Research Center, Yerevan, Armenia.
McIlleron H; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Moreau M; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Moschioni M; Medicines Patent Pool, Geneva, Switzerland.
Nahid P; UCSF Center for Tuberculosis, University of California, , San Francisco, San Francisco, CA, USA.
Osso E; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Oyewusi L; Partners In Health, Maseru, Lesotho.
Panda S; Indian Council of Medical Research Headquarters, New Delhi, India.; Indian Journal of Medical Research, New Delhi, India.
Pâquet A; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Thuong Huu P; Hanoi Lung Hospital, Hanoi, Vietnam.
Pichon L; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Rich ML; Partners In Health, Boston, MA, USA.; Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA.
Rupasinghe P; Institute of Tropical Medicine (ITM), Antwerp, Belgium.
Salahuddin N; Indus Hospital & Health Network, Karachi, Pakistan.
Sanchez Garavito E; Hospital Nacional Sergio E. Bernales, Lima, Peru.
Seung KJ; Partners In Health, Boston, MA, USA.
Velásquez GE; UCSF Center for Tuberculosis, University of California, , San Francisco, San Francisco, CA, USA.; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Vallet M; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Varaine F; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France.
Yuya-Septoh FJ; Epicentre, Paris, France.
Mitnick CD; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.; Partners In Health, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA.
Guglielmetti L; Medical Department, Médecins Sans Frontières, 14-34 Avenue Jean Jaurès, 75019, Paris, France. .; Sorbonne Université, INSERM, U1135, Centre d'Immunologie Et Des Maladies Infectieuses, Paris, France. .; Assistance Publique Hôpitaux de Paris (APHP), Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié Salpêtrière, Centre National De Référence Des Mycobactéries Et De La Résistance Des Mycobactéries Aux Antituberculeux, Paris, France. .
Pokaż więcej
Źródło:
Trials [Trials] 2023 Nov 30; Vol. 24 (1), pp. 773. Date of Electronic Publication: 2023 Nov 30.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/diagnosis
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Fluoroquinolones/adverse effects ; Clofazimine/adverse effects ; Linezolid/adverse effects ; Antitubercular Agents/adverse effects ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Call for special attention to the caregiver burden of patients with drug-resistant tuberculosis in low- and middle-income countries.
Autorzy:
Wu S; Department of Pulmonary Medicine and Tuberculosis, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Zhang H; Department of Pulmonary Medicine and Tuberculosis, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Wang Y; Department of Pulmonary Medicine and Tuberculosis, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Wang J; Department of Pulmonary Medicine and Tuberculosis, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Zhang P; Department of Pulmonary Medicine and Tuberculosis, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Asakawa T; Institute of Neurology, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Lin Y; Department of Pulmonary Medicine and Tuberculosis, National Clinical Research Center for Infectious Diseases, the Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Pokaż więcej
Źródło:
Bioscience trends [Biosci Trends] 2023 Nov 18; Vol. 17 (5), pp. 405-408. Date of Electronic Publication: 2023 Oct 14.
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Caregiver Burden ; Developing Countries ; Quality of Life
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
Autorzy:
Fadeyi MO; Nigeria office, Damien Foundation Belgium, Ibadan, Nigeria.
Decroo T; Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
Ortuño-Gutiérrez N; Damien Foundation, 1000 Brussels, Belgium.
Ahmed B; Nigeria office, Damien Foundation Belgium, Ibadan, Nigeria.
Jinadu A; Nigeria office, Damien Foundation Belgium, Ibadan, Nigeria.
El-Tayeb O; Damien Foundation, 1000 Brussels, Belgium.
Adebola W; Disease Elimination Program, Burnet Institute, 3004 Melbourne, Australia.
Kehinde A; Department of Medical Microbiology and Parasitology, University of Ibadan, Ibadan, Nigeria.
Lynen L; Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
Gils T; Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
Pokaż więcej
Źródło:
International health [Int Health] 2024 Jan 02; Vol. 16 (1), pp. 123-125.
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Antitubercular Agents/therapeutic use ; Clofazimine/therapeutic use ; Linezolid/therapeutic use ; Nigeria ; Prospective Studies ; Rifampin/pharmacology ; Rifampin/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR].
Autorzy:
Fu L; Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, 29 Bulan Rd, Longgang District, Shenzhen, 518112, China.
Xiong J; Health Science Center, Shenzhen University, 3688 Nanhai Avenue, Nanshan District, Shenzhen, 518060, China.
Wang H; Peking University Clinical Research Institute, Peking University First Hospital, Xueyuan Rd 38#, Haidian District, Beijing, 100000, 100191, China.
Zhang P; Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, 29 Bulan Rd, Longgang District, Shenzhen, 518112, China.
Yang Q; Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, 29 Bulan Rd, Longgang District, Shenzhen, 518112, China.
Cai Y; Department of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, 1066 Xueyuan Ave, Nanshan District, Shenzhen, 518060, China.
Wang W; Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, 29 Bulan Rd, Longgang District, Shenzhen, 518112, China.; Department of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, 1066 Xueyuan Ave, Nanshan District, Shenzhen, 518060, China.
Sun F; Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Jing'an District, Shanghai, 200040, China.
Zhang X; Tuberculosis Prevention and Control Department, The Fourth People's Hospital of Foshan, 106 Jinlannan Rd, Chancheng District, Foshan, 528000, China.
Wang Z; Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, 29 Bulan Rd, Longgang District, Shenzhen, 518112, China.
Chen X; Department of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, 1066 Xueyuan Ave, Nanshan District, Shenzhen, 518060, China. .
Zhang W; Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Jing'an District, Shanghai, 200040, China. .
Deng G; Division Two of Pulmonary Diseases Department, Shenzhen Third People's Hospital, Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, 29 Bulan Rd, Longgang District, Shenzhen, 518112, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Nov 27; Vol. 23 (1), pp. 834. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Antitubercular Agents/adverse effects ; Clinical Protocols ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Protocol for a systematic review of long-term physical sequelae and financial burden of multidrug-resistant and extensively drug-resistant tuberculosis.
Autorzy:
Akalu TY; School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.; Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Perth, Western Australia, Australia.; Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Clements ACA; Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Perth, Western Australia, Australia.; Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom.
Baraki AG; Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Alene KA; School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.; Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Perth, Western Australia, Australia.; Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 May 15; Vol. 18 (5), pp. e0285404. Date of Electronic Publication: 2023 May 15 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Humans ; Financial Stress ; Risk Factors ; Rifampin ; Antitubercular Agents/therapeutic use ; Systematic Reviews as Topic ; Meta-Analysis as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Costs of services and funding gap of the Bangladesh National Tuberculosis Control Programme 2016-2022: An ingredient based approach.
Autorzy:
Hasan MZ; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.; Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom.
Ahmed S; Health Economics and Health Technology Assessment (HEHTA), Institute of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom.
Islam Z; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Dorin F; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Rabbani MG; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mehdi GG; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Ahmed MW; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Tahsina T; Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Mahmood SS; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Islam Z; Health Economics and Financing, Health Systems and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Jun 02; Vol. 18 (6), pp. e0286560. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Budgets*
Extensively Drug-Resistant Tuberculosis*
Humans ; Bangladesh
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Metabolomic analysis of Mycobacterium tuberculosis reveals metabolic profiles for identification of drug-resistant tuberculosis.
Autorzy:
Chaiyachat P; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand.
Kaewseekhao B; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand.
Chaiprasert A; Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Kamolwat P; Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Nonghanphithak D; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand.
Phetcharaburanin J; Department of Systems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Sirichoat A; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand.
Ong RT; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Faksri K; Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. .; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 May 27; Vol. 13 (1), pp. 8655. Date of Electronic Publication: 2023 May 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Mycobacterium tuberculosis*/genetics
Extensively Drug-Resistant Tuberculosis*/microbiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Antitubercular Agents/therapeutic use ; Tandem Mass Spectrometry ; Drug Resistance, Multiple, Bacterial/genetics ; Ethionamide ; Ethambutol/pharmacology ; Metabolome ; Microbial Sensitivity Tests
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study.
Autorzy:
Pan Y; School of Public Health, Dalian Medical University, 9 West Section, Lushun South Road, Dalian, Liaoning Province, People's Republic of China.
Yu Y; School of Public Health, Dalian Medical University, 9 West Section, Lushun South Road, Dalian, Liaoning Province, People's Republic of China.
Yi Y; School of Public Health, Dalian Medical University, 9 West Section, Lushun South Road, Dalian, Liaoning Province, People's Republic of China.
Dou X; School of Public Health, Dalian Medical University, 9 West Section, Lushun South Road, Dalian, Liaoning Province, People's Republic of China.
Lu J; School of Public Health, Dalian Medical University, 9 West Section, Lushun South Road, Dalian, Liaoning Province, People's Republic of China.
Zhou L; School of Public Health, Dalian Medical University, 9 West Section, Lushun South Road, Dalian, Liaoning Province, People's Republic of China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Mar 15; Vol. 23 (1), pp. 162. Date of Electronic Publication: 2023 Mar 15.
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/complications
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/complications
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Diabetes Mellitus*/epidemiology
Diabetes Mellitus*/drug therapy
Humans ; Male ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Retrospective Studies ; Microbial Sensitivity Tests ; Kanamycin/therapeutic use ; China/epidemiology ; Drug Resistance
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Drug Resistance of Mycobacterium tuberculosis Based on Whole-Genome Sequencing in the Yi Ethnic Group, Sichuan Province, China.
Autorzy:
Gao W; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Chen X; Laboratory Medicine, Liangshan Yi Autonomous Prefecture Center for Disease Control and Prevention, Liangshan, Sichuan, China 615000.
Yao L; Laboratory Medicine, Butuo County People's Hospital, Liangshan, Sichuan, China 616350.
Li J; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Gao Y; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Li T; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Li Y; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Wang W; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Zhang S; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
He J; Institute for Tuberculosis Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China 610041.
Pokaż więcej
Źródło:
Journal of immunology research [J Immunol Res] 2023 Jan 23; Vol. 2023, pp. 4431209. Date of Electronic Publication: 2023 Jan 23 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Mycobacterium tuberculosis*/genetics
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
HIV Infections*/drug therapy
HIV Infections*/epidemiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Tuberculosis, Multidrug-Resistant*/microbiology
Male ; Humans ; Female ; Aged ; Ethnicity ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Drug Resistance, Multiple, Bacterial/genetics ; China/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Global trends, regional differences and age distribution for the incidence of HIV and tuberculosis co-infection from 1990 to 2019: results from the global burden of disease study 2019.
Autorzy:
Wang Y; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Jing W; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Liu J; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Liu M; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Pokaż więcej
Źródło:
Infectious diseases (London, England) [Infect Dis (Lond)] 2022 Nov; Vol. 54 (11), pp. 773-783. Date of Electronic Publication: 2022 Jul 07.
Typ publikacji:
Journal Article
MeSH Terms:
Coinfection*/drug therapy
Coinfection*/epidemiology
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
HIV Infections*/complications
HIV Infections*/drug therapy
HIV Infections*/epidemiology
Latent Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Age Distribution ; Aged ; Antitubercular Agents/therapeutic use ; Global Burden of Disease ; Humans ; Incidence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island.
Autorzy:
Loukman M; Service de Pneumologie, Centre Hospitalo-Universitaire Réunion, Allée des topazes CS 11021, 97400, Site St. Denis, France.
Olivier B; Service de Microbiologie, Centre Hospitalo-Universitaire Réunion, Site St. Denis, France.
Vincent B; Centre de Lutte Anti Tuberculeuse Sud Réunion, St. Denis, France.
Rachid D; Centre de Lutte Anti Tuberculeuse Ouest Réunion, St. Denis, France.
Cyril F; Methodological Support Unit, Saint-Denis University Hospital, St Denis, France.; Clinical Research Department, INSERM, CIC1410, 97410, Saint-Pierre, France.
Morgane V; Service de Pneumologie, Centre Hospitalo-Universitaire Réunion, Allée des topazes CS 11021, 97400, Site St. Denis, France.; Centre de Lutte Anti Tuberculeuse Nord-Est Réunion, St. Denis, France.
Nathalie CA; Service de Pneumologie, Centre Hospitalo-Universitaire Réunion, Allée des topazes CS 11021, 97400, Site St. Denis, France. .; Centre de Lutte Anti Tuberculeuse Nord-Est Réunion, St. Denis, France. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Jan 05; Vol. 23 (1), pp. 4. Date of Electronic Publication: 2023 Jan 05.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Antitubercular Agents*/therapeutic use
Extensively Drug-Resistant Tuberculosis*
Humans ; Female ; Reunion/epidemiology ; Comoros/epidemiology ; Madagascar/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.
Autorzy:
Zeynali Kelishomi F; Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Khanjani S; Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Fardsanei F; Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Saghi Sarabi H; Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
Nikkhahi F; Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. .
Dehghani B; Department of Bacteriology-Virology, Shiraz University of Medical Sciences, Shiraz, Iran.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2022 Dec 22; Vol. 22 (1), pp. 957. Date of Electronic Publication: 2022 Dec 22.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Mycobacterium tuberculosis*/genetics
Bacteriophages*
Tuberculosis, Multidrug-Resistant*/drug therapy
Extensively Drug-Resistant Tuberculosis*/drug therapy
Humans ; Antitubercular Agents/therapeutic use ; Antitubercular Agents/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Autorzy:
Pai H; Janssen Research & Development, LLC, Raritan, NJ, USA. .
Ndjeka N; National TB Programme, South African National Department of Health, Pretoria, South Africa.
Mbuagbaw L; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Kaniga K; Janssen Research & Development, LLC, Titusville, NJ, USA.
Birmingham E; Janssen Research & Development, LLC, Raritan, NJ, USA.
Mao G; Janssen Research & Development, LLC, Titusville, NJ, USA.
Alquier L; Janssen Research & Development, LLC, Raritan, NJ, USA.
Davis K; Janssen Research & Development, LLC, Titusville, NJ, USA.
Bodard A; Janssen Pharmaceutica NV, Beerse, Belgium.
Williams A; Janssen Pharmaceutica (Pty.) Ltd, Johannesburg, South Africa.
Van Tongel M; Janssen Pharmaceutica NV, Beerse, Belgium.
Thoret-Bauchet F; Janssen-Cilag, Issy-les-Moulineaux, France.
Omar SV; Centre for Tuberculosis, National Institute for Communicable Diseases/National Health Laboratory Services, Johannesburg, South Africa.
Bakare N; Janssen Global Public Health, Janssen Research & Development, LLC, Titusville, NJ, USA.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2022 Nov 21; Vol. 22 (1), pp. 870. Date of Electronic Publication: 2022 Nov 21.
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Humans ; Retrospective Studies ; South Africa ; Microbial Sensitivity Tests ; Antitubercular Agents/adverse effects ; Cohort Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates.
Autorzy:
Singh K; Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Sharma S; Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Banerjee T; Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Gupta A; Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
Anupurba S; Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India. shampa_.
Pokaż więcej
Źródło:
BMC microbiology [BMC Microbiol] 2022 Oct 03; Vol. 22 (1), pp. 236. Date of Electronic Publication: 2022 Oct 03.
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/microbiology
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/microbiology
Agar ; Antitubercular Agents/pharmacology ; Clofazimine/pharmacology ; Clofazimine/therapeutic use ; Cytosine/therapeutic use ; Drug Resistance, Multiple, Bacterial/genetics ; Humans ; Linezolid/pharmacology ; Linezolid/therapeutic use ; Microbial Sensitivity Tests ; Mutation ; Thymine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Autorzy:
Zhang SJ; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, 200433, China.
Yang Y; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, 200433, China.
Sun WW; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, 200433, China.
Zhang ZS; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, 200433, China.
Xiao HP; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, 200433, China.
Li YP; Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. .
Zhang ZM; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. .
Fan L; Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Shanghai, 200433, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2022 Aug 29; Vol. 22 (1), pp. 715. Date of Electronic Publication: 2022 Aug 29.
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/microbiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Pulmonary*/drug therapy
Antitubercular Agents/adverse effects ; Diarylquinolines ; Humans ; Retrospective Studies ; Rifampin/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Autorzy:
Dreyer V; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
Mandal A; The Foundation for Medical Research, Mumbai, India.
Dev P; The Foundation for Medical Research, Mumbai, India.
Merker M; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.; Evolution of the Resistome, Research Center Borstel, Borstel, Germany.; CRyPTIC Consortium, Oxford, UK.
Barilar I; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Utpatel C; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Nilgiriwala K; The Foundation for Medical Research, Mumbai, India.
Rodrigues C; Department of Microbiology, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Crook DW; CRyPTIC Consortium, Oxford, UK.; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Rasigade JP; Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, University of Lyon, Lyon, France.; Institut Des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
Wirth T; Institut de Systématique, Evolution, Biodiversité, UMR-CNRS 7205, Muséum National d'Histoire Naturelle, Université Pierre Et Marie Curie, Université Des Antilles, Ecole Pratique Des Hautes Etudes, Sorbonne Universités, Paris, France.; EPHE, PSL University, Paris, France.
Mistry N; The Foundation for Medical Research, Mumbai, India.
Niemann S; Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany. .; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany. .; CRyPTIC Consortium, Oxford, UK. .
Pokaż więcej
Corporate Authors:
CRyPTIC Consortium
Źródło:
Genome medicine [Genome Med] 2022 Aug 22; Vol. 14 (1), pp. 95. Date of Electronic Publication: 2022 Aug 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Extensively Drug-Resistant Tuberculosis*/microbiology
Mycobacterium tuberculosis*/genetics
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Tuberculosis, Multidrug-Resistant*/microbiology
Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Clone Cells ; Drug Resistance, Multiple, Bacterial/genetics ; Fluoroquinolones/pharmacology ; Fluoroquinolones/therapeutic use ; Humans ; Microbial Sensitivity Tests ; Multilocus Sequence Typing ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.
Corporate Authors:
The CRyPTIC Consortium
Źródło:
PLoS biology [PLoS Biol] 2022 Aug 09; Vol. 20 (8), pp. e3001721. Date of Electronic Publication: 2022 Aug 09 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/microbiology
Mycobacterium tuberculosis*/genetics
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/genetics
Tuberculosis, Multidrug-Resistant*/microbiology
Antitubercular Agents/pharmacology ; Drug Resistance, Multiple, Bacterial/genetics ; Humans ; Microbial Sensitivity Tests ; Mutation ; Phenotype ; Rifampin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
Autorzy:
Fekadu G; Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Yao J; Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, SAR, China.
You JHS; Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Aug 05; Vol. 17 (8), pp. e0272770. Date of Electronic Publication: 2022 Aug 05 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Tuberculosis, Multidrug-Resistant*/drug therapy
Adult ; Antitubercular Agents ; Cost-Benefit Analysis ; Diarylquinolines ; Humans ; South Africa
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.
Autorzy:
Sy KTL; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
Leavitt SV; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
de Vos M; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Dolby T; National Health Laboratory Service, Cape Town, South Africa.
Bor J; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Horsburgh CR Jr; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.; Department of Global Health, Boston University School of Public Health, Boston, MA, USA.; Section of Infectious Diseases, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.
Warren RM; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Streicher EM; DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jenkins HE; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Jacobson KR; Section of Infectious Diseases, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 27; Vol. 12 (1), pp. 10844. Date of Electronic Publication: 2022 Jun 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Extensively Drug-Resistant Tuberculosis*/drug therapy
Extensively Drug-Resistant Tuberculosis*/epidemiology
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant*/drug therapy
Tuberculosis, Multidrug-Resistant*/epidemiology
Amikacin/pharmacology ; Amikacin/therapeutic use ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Fluoroquinolones/pharmacology ; Fluoroquinolones/therapeutic use ; Humans ; Microbial Sensitivity Tests ; Ofloxacin ; South Africa/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 533

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies